tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

IMUX Stock Latest News

Immunic Buy Rating: Undervalued Next-Generation Oral MS Therapy with Key Phase III Catalysts and Strategic Partnership Upside
RatingsImmunic Buy Rating: Undervalued Next-Generation Oral MS Therapy with Key Phase III Catalysts and Strategic Partnership Upside
7d ago
IMUX
Immunic Transfers Listing to Nasdaq Capital Market for Compliance
PremiumCompany Announcements
Immunic Transfers Listing to Nasdaq Capital Market for Compliance
8d ago
8K
IMUX
Immunic price target lowered to $8 from $10 at H.C. Wainwright
PremiumThe Fly
Immunic price target lowered to $8 from $10 at H.C. Wainwright
2M ago
IMUX
Immunic, Inc. Reports Q3 2025 Financial Results
PremiumCompany Announcements
Immunic, Inc. Reports Q3 2025 Financial Results
2M ago
IMUX
Immunic’s Promising Market Potential: Buy Rating Backed by Vidofludimus Calcium’s Efficacy, Safety, and Strategic Financial Path
PremiumRatings
Immunic’s Promising Market Potential: Buy Rating Backed by Vidofludimus Calcium’s Efficacy, Safety, and Strategic Financial Path
2M ago
IMUX
Immunic reports Q3 EPS (13c), consensus (18c)
PremiumThe FlyImmunic reports Q3 EPS (13c), consensus (18c)
2M ago
IMUX
Datadog, Trade Desk upgraded: Wall Street’s top analyst calls
Premium
The Fly
Datadog, Trade Desk upgraded: Wall Street’s top analyst calls
2M ago
U
PI
Immunic initiated with a Buy at Roth Capital
Premium
The Fly
Immunic initiated with a Buy at Roth Capital
2M ago
IMUX
IMUX Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
IMUX Upcoming Earnings Report: What to Expect?
2M ago
IMUX
Immunic’s Vidofludimus Calcium: A Promising MS Treatment with Unique Mechanism and Phase 3 Progress
PremiumRatings
Immunic’s Vidofludimus Calcium: A Promising MS Treatment with Unique Mechanism and Phase 3 Progress
3M ago
IMUX
Immunic initiated with a Buy at Ladenburg
PremiumThe Fly
Immunic initiated with a Buy at Ladenburg
3M ago
IMUX
Immunic management to meet with B. Riley
PremiumThe Fly
Immunic management to meet with B. Riley
3M ago
IMUX
Immunic initiated with a Buy at Chardan
PremiumThe FlyImmunic initiated with a Buy at Chardan
4M ago
IMUX
Buy Rating Affirmed for Immunic’s Vidofludimus Calcium Amid Promising MS Trial Results
Premium
Ratings
Buy Rating Affirmed for Immunic’s Vidofludimus Calcium Amid Promising MS Trial Results
4M ago
IMUX
Immunic Presents Promising Phase 2 Trial Results
Premium
Company Announcements
Immunic Presents Promising Phase 2 Trial Results
4M ago
8K
IMUX
Immunic receives notice of allowance for vidofludimus calcium patent
PremiumThe Fly
Immunic receives notice of allowance for vidofludimus calcium patent
4M ago
IMUX
Promising Efficacy and Safety of Vidofludimus Calcium in MS Trials Reinforces Buy Rating
PremiumRatings
Promising Efficacy and Safety of Vidofludimus Calcium in MS Trials Reinforces Buy Rating
5M ago
IMUX
Immunic, Inc. Advances Multiple Sclerosis Drug Trials
PremiumCompany Announcements
Immunic, Inc. Advances Multiple Sclerosis Drug Trials
5M ago
IMUX
Immunic Advances Phase 3 Trials and Financial Health
PremiumCompany Announcements
Immunic Advances Phase 3 Trials and Financial Health
5M ago
8K
IMUX
Immunic reports Q2 EPS (20c), consensus (16c)
PremiumThe FlyImmunic reports Q2 EPS (20c), consensus (16c)
5M ago
IMUX
Immunic announces vidofludimus calcium trial data
Premium
The Fly
Immunic announces vidofludimus calcium trial data
7M ago
IMUX
Immunic completes enrollment for both ENSURE trials
Premium
The Fly
Immunic completes enrollment for both ENSURE trials
7M ago
IMUX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >